This page provides a list of some of the company’s key events in the near future. An Investor Relations calendar can be found here.

Upcoming events

Herantis newsletter for January-February
Company presentation for Osakesäästäjät in Helsinki
Herantis presenting at ABGSC Investor Days at Haymarket
02.04 - 05.04.2020
Herantis at AAT-AD/PD in Vienna (Advances in Alzheimer’s and Parkinson’s Therapies)
Lymfactin presentation at 99th AAPS meeting – American Association of Plastic Surgeons
Herantis newsletter for March-April
Sijoitusmessut investor event in Tampere
Herantis at ABGSC Life Science Summit
Public materials related to our company and products will be presented on this page. Presentations in Finnish language can be found here. Please note that these presentations are provided for historical use only. Herantis will not keep these presentations up-to-date after their actual presenting date.

Links to public video presentations are provided on this page. Video presentation in Finnish language can be found here.
Videos specific to the drug candidates of Herantis can be found under Patients
PLEASE NOTE: the presentations are for historical use only. The presentations are not kept up-to-date after their actual presenting date.

Cool life-changing stuff from the Nordics

"In digital health, we only invest in Nordics and the USA." (An international life sciences investor)

World Bioethics Day is a good day to learn about bioethics

Did you know that Bioethics is a very broad and challenging branch of science with potentially significant impact on our future?

How to invest smartly in biotech?

The big difference in biotech investments compared to more established businesses is that you need to assess a possible future success rather than consider existing cash flow and profit.

Artificially intelligent drug development

Artificial intelligence (AI) will shape our world in the coming years. People already speculate how AI can superhumanly solve any human problem. What will its role be in healthcare?

The price of life (and drugs)

Developing of novel drugs is always a high-risk endeavor and success should result in a financial reward. However, what is an acceptable cost for the treatment of severe rare disorders?

How big is big: The economic burden of disease

The global direct healthcare costs are approaching $10 trillion. What does that signify? The CEO gives a concrete example to elucidate the potential significance of our work.

Big Pharma and risk acceptance for true innovation

The development of new drugs is always risky. The more innovative an approach is the higher are the risks. For a real breakthrough in an unmet clinical need, high risk acceptance is needed.

A different view to Parkinson’s disease

Seppo Nieminen, a Parkinson's patient active in the regional Parkinson's group of Keski-Uusimaa in Finland, gives his thoughts on the current publishing practice on news in Parkinson's.